Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  • Home
Article
  • Cited by 8

  • Access

Dietary supplementation of trans-11-vaccenic acid reduces adipocyte size but neither aggravates nor attenuates obesity-mediated metabolic abnormalities in fa/fa Zucker rats

  • Suresh K. Mohankumar (a1) (a2), Danielle Hanke (a1) (a2), Linda Siemens (a1) (a2), Alexander Cattini (a2) (a3), Jennifer Enns (a2) (a3), Jianheng Shen (a4), Martin Reaney (a4), Peter Zahradka (a1) (a2) (a3) and Carla G. Taylor (a1) (a2) (a3)...

Abstract

Conjugated linoleic acid (CLA) present in dairy and ruminant fat has beneficial effects on metabolic syndrome characteristics in humans and some rodent models. Production practices to increase the milk content of CLA are also substantially elevating trans-11-vaccenic acid (VA). Questions are being raised whether VA has the same beneficial actions as CLA or has adverse biological effects similar to industrially produced trans-fatty acids. The present study examined the effects of dietary supplementation of either 0 or 1·5 % (w/w) VA for 8 weeks on lipidaemia, glycaemia, blood pressure, hepatic steatosis, adipocyte size and molecular markers of inflammation and insulin signalling in fa/fa Zucker rats. Dietary supplementation of VA did not alter feed intake, weight gain, blood pressure or organ:body weight (BW) ratios, except the epididymal fat:BW ratio which was lower in the VA group compared with the control group. The total liver lipid concentration as an indicator of hepatic steatosis was not different between the groups. Likewise, there were no changes in fasting lipidaemia, glycaemia or oral glucose tolerance. Although there were no physiological differences observed between the groups, animals supplemented with VA had smaller adipocytes (approximately 7 % smaller than the controls). The VA group also had higher adipophilin and IL-10 protein levels in epididymal adipose tissue (1·7- and 1·4-fold higher than the controls, respectively); however, there were no changes observed in critical nodes of insulin signalling. The present study provides evidence that supplementation with VA, a naturally produced trans-fat, has some positive effects on adipose tissue and did not exacerbate obesity-mediated metabolic abnormalities.

  • View HTML

      • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Dietary supplementation of trans-11-vaccenic acid reduces adipocyte size but neither aggravates nor attenuates obesity-mediated metabolic abnormalities in fa/fa Zucker rats
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Dietary supplementation of trans-11-vaccenic acid reduces adipocyte size but neither aggravates nor attenuates obesity-mediated metabolic abnormalities in fa/fa Zucker rats
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Dietary supplementation of trans-11-vaccenic acid reduces adipocyte size but neither aggravates nor attenuates obesity-mediated metabolic abnormalities in fa/fa Zucker rats
      Available formats
      ×

Copyright

COPYRIGHT: © The Authors 2012

Corresponding author

*Corresponding author: Dr C. G. Taylor, fax +1 204 2374018, email: ctaylor@cc.umanitoba.ca

References

Hide All
1Moller, DE & Kaufman, KD (2005) Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 56, 45–62.
2Ford, ES, Li, C & Sattar, N (2008) Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 31, 1898–1904.
3Mottillo, S, Filion, KB, Genest, J, et al. (2010) The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56, 1113–1132.
4Kimokoti, RW & Brown, LS (2011) Dietary management of the metabolic syndrome. Clin Pharmacol Ther 90, 184–187.
5Riccardi, G, Giacco, R & Rivellese, AA (2004) Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 23, 447–456.
6Bray, GA, Paeratakul, S & Popkin, BM (2004) Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiol Behav 83, 549–555.
7Ryder, JW, Portocarrero, CP, Song, XM, et al. (2001) Isomer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression. Diabetes 50, 1149–1157.
8Noone, EJ, Roche, HM, Nugent, AP, et al. (2002) The effect of dietary supplementation using isomeric blends of conjugated linoleic acid on lipid metabolism in healthy human subjects. Br J Nutr 88, 243–251.
9Henriksen, EJ, Teachey, MK, Taylor, ZC, et al. (2003) Isomer-specific actions of conjugated linoleic acid on muscle glucose transport in the obese Zucker rat. Am J Physiol Endocrinol Metab 285, E98–E105.
10Nagao, K, Inoue, N, Wang, YM, et al. (2003) Conjugated linoleic acid enhances plasma adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty (fa/fa) rats. Biochem Biophys Res Commun 310, 562–566.
11Inoue, N, Nagao, K, Hirata, J, et al. (2004) Conjugated linoleic acid prevents the development of essential hypertension in spontaneously hypertensive rats. Biochem Biophys Res Commun 323, 679–684.
12Moloney, F, Yeow, TP, Mullen, A, et al. (2004) Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. Am J Clin Nutr 80, 887–895.
13Choi, JS, Jung, MH, Park, HS, et al. (2004) Effect of conjugated linoleic acid isomers on insulin resistance and mRNA levels of genes regulating energy metabolism in high-fat-fed rats. Nutrition 20, 1008–1017.
14Noto, A, Zahradka, P, Yurkova, N, et al. (2006) Conjugated linoleic acid reduces hepatic steatosis, improves liver function, and favorably modifies lipid metabolism in obese insulin-resistant rats. Lipids 41, 179–188.
15Noto, A, Zahradka, P, Yurkova, N, et al. (2007) Dietary conjugated linoleic acid decreases adipocyte size and favorably modifies adipokine status and insulin sensitivity in obese, insulin-resistant rats. Metabolism 56, 1601–1611.
16Noto, A, Zahradka, P, Ryz, NR, et al. (2007) Dietary conjugated linoleic acid preserves pancreatic function and reduces inflammatory markers in obese, insulin-resistant rats. Metabolism 56, 142–151.
17Moloney, F, Toomey, S, Noone, E, et al. (2007) Antidiabetic effects of cis-9, trans-11-conjugated linoleic acid may be mediated via anti-inflammatory effects in white adipose tissue. Diabetes 56, 574–582.
18Halade, GV, Rahman, MM & Fernandes, G (2010) Differential effects of conjugated linoleic acid isomers in insulin-resistant female C57Bl/6J mice. J Nutr Biochem 21, 332–337.
19Gilbert, W, Gadang, V, Proctor, A, et al. (2011) trans–trans Conjugated linoleic acid enriched soybean oil reduces fatty liver and lowers serum cholesterol in obese Zucker rats. Lipids 46, 961–968.
20Declercq, V, Taylor, CG, Wigle, J, et al. (2012) Conjugated linoleic acid improves blood pressure by increasing adiponectin and endothelial nitric oxide synthase activity. J Nutr Biochem 23, 487–493.
21Tsuboyama-Kasaoka, N, Takahashi, M, Tanemura, K, et al. (2000) Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. Diabetes 49, 1534–1542.
22Chung, S, Brown, JM, Provo, JN, et al. (2005) Conjugated linoleic acid promotes human adipocyte insulin resistance through NFkappaB-dependent cytokine production. J Biol Chem 280, 38445–38456.
23Wendel, AA, Purushotham, A, Liu, LF, et al. (2008) Conjugated linoleic acid fails to worsen insulin resistance but induces hepatic steatosis in the presence of leptin in ob/ob mice. J Lipid Res 49, 98–106.
24de Roos, B, Rucklidge, G, Reid, M, et al. (2005) Divergent mechanisms of cis9, trans11-and trans10, cis12-conjugated linoleic acid affecting insulin resistance and inflammation in apolipoprotein E knockout mice: a proteomics approach. FASEB J 19, 1746–1748.
25Cruz-Hernandez, C, Kramer, JK, Kennelly, JJ, et al. (2007) Evaluating the conjugated linoleic acid and trans 18:1 isomers in milk fat of dairy cows fed increasing amounts of sunflower oil and a constant level of fish oil. J Dairy Sci 90, 3786–3801.
26Lock, AL & Bauman, DE (2004) Modifying milk fat composition of dairy cows to enhance fatty acids beneficial to human health. Lipids 39, 1197–1206.
27Corl, BA, Barbano, DM, Bauman, DE, et al. (2003) cis-9, trans-11 CLA derived endogenously from trans-11 18:1 reduces cancer risk in rats. J Nutr 133, 2893–2900.
28Turpeinen, AM, Mutanen, M, Aro, A, et al. (2002) Bioconversion of vaccenic acid to conjugated linoleic acid in humans. Am J Clin Nutr 76, 504–510.
29Sommerfeld, M (1983) Trans unsaturated fatty acids in natural products and processed foods. Prog Lipid Res 22, 221–233.
30Chisholm, A, Mann, J & Skeaff, M (1995) Trans fatty acids: a cause for concern? Int J Food Sci Nutr 46, 171–176.
31Woodside, JV & Kromhout, D (2005) Fatty acids and CHD. Proc Nutr Soc 64, 554–564.
32Ascherio, A, Hennekens, CH, Buring, JE, et al. (1994) Trans-fatty acids intake and risk of myocardial infarction. Circulation 89, 94–101.
33Tholstrup, T (2006) Dairy products and cardiovascular disease. Curr Opin Lipidol 17, 1–10.
34Sun, Q, Ma, J, Campos, H, et al. (2007) A prospective study of trans fatty acids in erythrocytes and risk of coronary heart disease. Circulation 115, 1858–1865.
35Bendsen, NT, Christensen, R, Bartels, EM, et al. (2011) Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies. Eur J Clin Nutr 65, 773–783.
36Wang, Y, Jacome-Sosa, MM, Ruth, MR, et al. (2009) Trans-11 vaccenic acid reduces hepatic lipogenesis and chylomicron secretion in JCR:LA-cp rats. J Nutr 139, 2049–2054.
37Wang, Y, Lu, J, Ruth, MR, et al. (2008) Trans-11 vaccenic acid dietary supplementation induces hypolipidemic effects in JCR:LA-cp rats. J Nutr 138, 2117–2122.
38Jacome-Sosa, MM, Lu, J, Wang, Y, et al. (2010) Increased hypolipidemic benefits of cis-9, trans-11 conjugated linoleic acid in combination with trans-11 vaccenic acid in a rodent model of the metabolic syndrome, the JCR:LA-cp rat. Nutr Metab (Lond) 7, 60.
39Bassett, CM, Edel, AL, Patenaude, AF, et al. (2010) Dietary vaccenic acid has antiatherogenic effects in LDLr − / −  mice. J Nutr 140, 18–24.
40Kurtz, TW, Morris, RC & Pershadsingh, HA (1989) The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13, 896–901.
41Kasiske, BL, O'Donnell, MP & Keane, WF (1992) The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19, I110–I115.
42Duffy, PE, Quinn, SM, Roche, HM, et al. (2006) Synthesis of trans-vaccenic acid and cis-9-trans-11-conjugated linoleic acid. Tetrahedron 62, 4838–4843.
43Declercq, V, Taylor, CG & Zahradka, P (2012) Isomer-specific effects of conjugated linoleic acid on blood pressure, adipocyte size and function. Br J Nutr 107, 1413–1421.
44Brouns, F, Bjorck, I, Frayn, KN, et al. (2005) Glycaemic index methodology. Nutr Res Rev 18, 145–171.
45Sethi, JK & Vidal-Puig, AJ (2007) Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 48, 1253–1262.
46Tchoukalova, YD, Votruba, SB, Tchkonia, T, et al. (2010) Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. Proc Natl Acad Sci U S A 107, 18226–18231.
47Lonn, M, Mehlig, K, Bengtsson, C, et al. (2010) Adipocyte size predicts incidence of type 2 diabetes in women. FASEB J 24, 326–331.
48Stender, S, Astrup, A & Dyerberg, J (2008) Ruminant and industrially produced trans fatty acids: health aspects. Food Nutr Res 52 (Epublication 12 March 2008).
49Mendis, S, Cruz-Hernandez, C & Ratnayake, WM (2008) Fatty acid profile of Canadian dairy products with special attention to the trans-octadecenoic acid and conjugated linoleic acid isomers. J AOAC Int 91, 811–819.
50Tholstrup, T, Raff, M, Basu, S, et al. (2006) Effects of butter high in ruminant trans and monounsaturated fatty acids on lipoproteins, incorporation of fatty acids into lipid classes, plasma C-reactive protein, oxidative stress, hemostatic variables, and insulin in healthy young men. Am J Clin Nutr 83, 237–243.
51Tardy, AL, Lambert-Porcheron, S, Malpuech-Brugere, C, et al. (2009) Dairy and industrial sources of trans fat do not impair peripheral insulin sensitivity in overweight women. Am J Clin Nutr 90, 88–94.
52Fruhbeck, G (2008) Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol Biol 456, 1–22.
53Azain, MJ, Hausman, DB, Sisk, MB, et al. (2000) Dietary conjugated linoleic acid reduces rat adipose tissue cell size rather than cell number. J Nutr 130, 1548–1554.
54DeClercq, V, Zahradka, P & Taylor, CG (2010) Dietary t10, c12-CLA but not c9, t11 CLA reduces adipocyte size in the absence of changes in the adipose renin–angiotensin system in fa/fa Zucker rats. Lipids 45, 1025–1033.
55Skurk, T, Alberti-Huber, C, Herder, C, et al. (2007) Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92, 1023–1033.
56Kershaw, EE & Flier, JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89, 2548–2556.
57Couper, KN, Blount, DG & Riley, EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180, 5771–5777.
58Bogaert, YE & Linas, S (2009) The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol 5, 101–111.
59Yvan-Charvet, L, Massiera, F, Lamande, N, et al. (2009) Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology 150, 1421–1428.
60Duke, LM, Evans, RG & Widdop, RE (2005) AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats. Am J Physiol Heart Circ Physiol 288, H2289–H2297.
61Srinivasan, K & Ramarao, P (2007) Animal models in type 2 diabetes research: an overview. Indian J Med Res 125, 451–472.

Keywords

  • Cited by 8

  • Access

Dietary supplementation of trans-11-vaccenic acid reduces adipocyte size but neither aggravates nor attenuates obesity-mediated metabolic abnormalities in fa/fa Zucker rats

  • Suresh K. Mohankumar (a1) (a2), Danielle Hanke (a1) (a2), Linda Siemens (a1) (a2), Alexander Cattini (a2) (a3), Jennifer Enns (a2) (a3), Jianheng Shen (a4), Martin Reaney (a4), Peter Zahradka (a1) (a2) (a3) and Carla G. Taylor (a1) (a2) (a3)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed